Cannabizetol: The Next Anti-Inflammatory Cannabinoid

Cannabis research continues to surprise the scientific community, uncovering new compounds that could expand the plant’s already impressive therapeutic range.  A recent study¹ published in The Journal of Natural Products introduced a brand-new cannabinoid called cannabizetol (CBGD).  This discovery may open new doors in anti-inflammatory medicine and skin health.

Understanding the Discovery

Cannabis sativa produces over 150 known cannabinoids, the best-known being THC, CBD, and CBG.  Most others exist only in trace amounts and are called minor cannabinoids.  Because these appear in such small concentrations, scientists often struggle to isolate and study them.  To overcome this, the researchers in this study synthesized cannabizetol in the lab and confirmed it also occurs naturally in hemp plants.

Cannabizetol is part of a rare class of compounds known as methylene-bridged dimeric cannabinoids, which means it forms when two cannabinoid molecules join together through a special chemical bond.  This structural feature may explain its unique biological behavior, offering more substantial or different effects than its individual parts.

How Scientists Created and Detected Cannabizetol

The researchers started with cannabigerol (CBG)—often referred to as the “mother of cannabinoids” because it is the precursor to many others like THC and CBD.  By using a controlled chemical reaction involving formaldehyde, they were able to create cannabizetol in the lab.  After verifying its structure, they looked for it in hemp extracts and successfully identified it in small amounts.  This confirmed cannabizetol as a naturally occurring cannabinoid rather than just a lab artifact.

Symbolic molecular overlay representing the discovery of cannabizetol (CBGD) in cannabis research.

Although only found in trace quantities (less than 0.1% of the plant extract), the ability to synthesize cannabizetol now makes it possible to study its effects more deeply.

Testing Cannabizetol’s Anti-Inflammatory Effects

To see whether cannabizetol had beneficial medical properties, scientists tested it alongside another dimeric cannabinoid called cannabitwinol (CBDD) using human skin cell models (HaCaT cells).  These cells are commonly used to study skin inflammation.

Both compounds exhibited vigorous anti-inflammatory activity, with cannabizetol standing out.  It was able to suppress inflammatory signals—particularly by reducing IL-8, a key molecule that drives inflammation in skin conditions like eczema, psoriasis, and dermatitis.  Even at very low concentrations, cannabizetol effectively blocked IL-8 production, suggesting it could calm inflammation without damaging cells.

The study also examined how these compounds affected NF-κB, a protein complex that controls many genes involved in inflammation.  Cannabizetol was a potent inhibitor of this pathway, showing stronger activity than both cannabitwinol and its parent compound CBG.  In simple terms, it appeared to switch off several genes that promote inflammation.

Swipe to scroll →

What Makes This Discovery Important

This finding is significant for several reasons.  First, it expands the list of known cannabinoids, proving that the cannabis plant’s chemistry is still far from fully mapped.  Second, it highlights that these minor cannabinoids could have potent effects even in small amounts.  Cannabizetol may eventually be used in topical products—like creams or gels—to treat inflammatory skin diseases without the side effects associated with steroids or synthetic drugs.

Beyond dermatology, the anti-inflammatory and antioxidant effects of cannabizetol could be beneficial for a range of conditions linked to chronic inflammation, including arthritis, autoimmune disorders, and neuroinflammation.  However, these possibilities remain speculative until further studies, including animal and clinical research, confirm their safety and effectiveness.

Looking Toward the Future

The discovery of cannabizetol also shows how modern chemistry and cannabis science can work hand in hand.  The researchers used flow chemistry, a technique that allows precise, continuous reactions under controlled conditions, to streamline synthesis.  This approach reduced reaction time from days to just over an hour while maintaining product quality.  Such efficiency could make it easier to produce research-grade cannabinoids for further testing and potential drug development.

Moreover, identifying cannabizetol opens the door for discovering similar “dimeric” cannabinoids that may exist in the plant but have not yet been found.  Each new compound provides another opportunity to explore how cannabinoids interact with our body’s endocannabinoid system, which regulates mood, pain, immunity, and inflammation.

The Bigger Picture for Cannabis Research

Studies like this reinforce a growing realization: cannabis is not defined solely by THC or CBD.  It is a complex botanical library filled with molecules that could help treat a range of health conditions.  By studying the lesser-known cannabinoids, scientists can uncover new biological pathways and therapies that don’t rely on intoxication or dependence.

In the case of cannabizetol, early results suggest a non-psychoactive, highly bioactive molecule capable of reducing inflammation at the cellular level.  This could inspire future treatments where cannabinoids are used not just for symptom relief but as targeted, natural anti-inflammatory agents.

As research expands, likely, more minor cannabinoids—once thought too rare to matter—will take the spotlight.  Each one adds another piece to the puzzle of how cannabis works in the body, bringing us closer to using this plant’s full potential in modern medicine.

References:

^{1. Pozzi, L., Gotti, A., Fumagalli, M., Citarella, A., Fasano, V., Paladino, G., Ciriello, U., Princiotto, S., Annunziata, F., Martinelli, G., Sangiovanni, E., Pinto, A., Dell’Agli, M., & Passarella, D. (2025). Cannabizetol, a novel cannabinoid: Chemical synthesis, anti-inflammatory activity, and extraction from Cannabis sativa L. Journal of Natural Products. https://doi.org/10.1021/acs.jnatprod.5c00826}